Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion

摘要: Vascular occlusion is one of the major causes mortality and morbidity. Blood vessel blockage can lead to thrombotic complications such as myocardial infarction, stroke, deep venous thrombosis, peripheral occlusive disease, pulmonary embolism. Thrombolytic therapy currently aims rectify this through administration recombinant tissue plasminogen activator. Research underway design an ideal thrombolytic drug with lowest risk. Despite potent clot lysis achievable using approved drugs alteplase, reteplase, streptokinase, tenecteplase, some other fibrinolytic agents, there are drawbacks, high production cost, systemic bleeding, intracranial hemorrhage, re-occlusion by platelet-rich retracted secondary clots, non-fibrin specificity. In comparison, bacterial staphylokinase, a new, small-size activator, unlike it hinders degradation fibrinogen reduces risk severe hemorrhage. A fibrin-bound plasmin-staphylokinase complex shows resistance a2-antiplasmin-related inhibition. Staphylokinase has potential be considered promising agent properties cost-effective least side effects.